opnurasib (JDQ443)

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

KRAS G12C inhibitor

Related drugs:

KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	JDQ443 Sensitive: C2 – Inclusion Criteria JDQ443 Sensitive : C2	JDQ443 Sensitive: C2 – Inclusion Criteria JDQ443 Sensitive : C2
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	TNO155 + JDQ443 Sensitive: D – Preclinical TNO155 + JDQ443 Sensitive : D	TNO155 + JDQ443 Sensitive: D – Preclinical TNO155 + JDQ443 Sensitive : D

Associations
(2)